Knowledge Hub
Research
Original research on buyer behaviour, AI visibility trends and pharmaceutical digital visibility, establishing Emerivo’s authority in the category.
Research articles
Why Pharma Buyers Now Start Supplier Discovery With AI
Procurement and BD teams increasingly ask AI tools to shortlist manufacturing and research partners before they ever open a search engine. Here is what that shift means for suppliers.
Read moreAI Visibility Is Not the Same Discipline as SEO
Ranking on Google and being recommended by AI are governed by different mechanics. Understanding the difference matters for where you invest.
Read moreWhy AI Discovery Is Harder — and More Important — in Regulated Manufacturing
Certifications, regulatory approvals and technical capability are difficult for general-purpose AI models to interpret correctly. That creates both risk and opportunity for pharma suppliers.
Read moreWhy Indian Pharmaceutical Manufacturers Are Disproportionately Invisible to AI
Indian manufacturers often have world-class capability but a fragmented digital footprint — and that combination is exactly what AI models struggle to understand.
Read moreCrawlable Is Not the Same as Visible: Why Passing Google Isn’t Enough
A website can satisfy Google and still be effectively invisible to the AI systems buyers now use. The two are not the same test.
Read moreIllustrative or Fabricated? How to Read AI Visibility Claims
As AI visibility becomes a category, so do inflated claims. A short guide to telling genuine evidence from confident-sounding invention.
Read moreWhy Overseas Pharma Buyers Are Changing How They Discover CDMOs
Pharma buyers now build their first shortlist through AI assistants — often before your website is ever visited. Why AI Visibility matters for CDMOs competing internationally.
Read moreFive Questions an Overseas Buyer May Ask AI Before Contacting Your Company
Overseas pharma buyers now ask AI to shortlist CDMOs before making contact. Five questions that reveal how legible your company really is.
Read moreWhy Some Pharmaceutical Manufacturers Are Shortlisted Before the First Sales Call
Pharma buyers narrow their CDMO shortlist before making contact — and legibility, not excellence, often decides who survives that first invisible cut.
Read moreSeven Trust Signals Every Pharmaceutical Website Should Demonstrate
The seven checkable trust signals that let an overseas buyer — or an AI assistant — judge your pharmaceutical company as credible before the first call.
Read moreHow Procurement Teams Can Use AI to Evaluate Manufacturing Partners
AI can widen supplier research but not judge quality. How pharmaceutical procurement teams can use AI to evaluate manufacturing partners — without being misled.
Read moreThe Questions Buyers Ask Before They Shortlist You — And How to Be Ready
Five questions buyers answer before contacting your company — and how to make your public presence answer them clearly before you’re in the room.
Read moreYour Pharmaceutical Website Is No Longer Just a Brochure
Why pharmaceutical websites now need to make genuine capabilities clear to buyers and AI assistants before the first enquiry.
Read moreTen Website Elements That Build Buyer Confidence
Ten specific, checkable elements that make a CDMO’s genuine capabilities clear to buyers and AI assistants before the first enquiry.
Read moreWhen AI Recommends a CDMO, What Is It Actually Evaluating?
An AI recommendation is a description of your legibility, not a ranking of quality. How a CDMO should read what AI says about it.
Read moreUnderstanding the Digital Signals That Influence AI Recommendations
Which signals in a CDMO’s public record make a genuine capability easier — or harder — for an AI assistant to establish. A practical guide.
Read moreSee how this applies to your organisation
Request an AI Discovery Audit™ to get a company-specific version of this analysis.